Total patients with SLE (N=1022) | SILD IV-CYC (n=506) | HD IV-CYC (n=256) | P value (SILD vs HD) | |
Sex (female:male) | 934:88 | 463:43 | 234:22 | 0.964 |
Age (years) | 39.00 (30.00–50.00) | 40.00 (31.00–51.00) | 39.00 (30.00–50.00) | 0.699 |
Age onset (years) | 31.00 (23.00–42.00) | 32.00 (24.00–43.00) | 31.50 (23.00–42.00) | 0.421 |
CYC course (months) | 6.00 (3.00–10.00) | 6.00 (3.00–10.63) | 6.00 (4.00–8.75) | 0.471 |
Accumulated dose of CYC (g) | 4.80 (2.40–8.00) | 4.80 (2.40–8.40) | 5.60 (3.20–8.00) | 0.139 |
Glucocorticoid dose (mg/day) | 20.00 (10.00–40.00) | 20.00 (10.00–45.00) | 18.75 (10.00–35.00) | 0.089 |
Lupus nephritis | 573 (56.07) | 269 (53.16) | 149 (58.20) | 0.187 |
Leucocytopaenia | 110 (10.76) | 66 (13.04) | 32 (12.5) | 0.832 |
Neutrocytopaenia | 20 (1.96) | 7 (1.38) | 3 (1.17) | 1.000 |
Lymphocytopaenia | 42 (4.11) | 23 (4.55) | 10 (3.91) | 0.682 |
Interstitial lung disease | 80 (7.83) | 45 (8.89) | 16 (6.25) | 0.204 |
Pulmonary arterial hypertension | 46 (4.50) | 26 (5.14) | 7 (2.73) | 0.124 |
NPSLE | 143 (13.99) | 70 (13.83) | 30 (11.72) | 0.414 |
Diabetes mellitus | 41 (4.01) | 19 (3.75) | 10 (3.91) | 0.918 |
Decreased C3 | 495 (48.43) | 249 (49.21) | 118 (46.09) | 0.416 |
Decreased C4 | 427 (41.78) | 186 (36.76) | 110 (42.97) | 0.097 |
Increased anti-dsDNA antibody | 317 (31.02) | 149 (29.45) | 77 (30.08) | 0.857 |
SLEDAI | 6.00 (2.00–10.00) | 6.00 (2.00–10.00) | 6.00 (2.00–9.00) | 0.316 |
HCQ | 881 (86.20) | 450 (88.93) | 221 (86.33) | 0.295 |
Glucocorticoid pulse therapy | 109 (10.67) | 52 (10.28) | 27 (10.55) | 0.908 |
Immunosuppressants before IV-CYC | ||||
MMF | 148 (14.48) | 80 (15.81) | 39 (15.23) | 0.836 |
AZA | 15 (1.47) | 11 (2.17) | 2 (0.78) | 0.269 |
CSA | 23 (2.25) | 13 (2.57) | 7 (2.73) | 0.893 |
TAC | 10 (0.98) | 9 (1.78) | 1 (0.39) | 0.210 |
MTX | 16 (1.57) | 10 (1.98) | 4 (1.56) | 0.908 |
LEF | 50 (4.89) | 29 (5.73) | 11 (4.30) | 0.402 |
RTX | 7 (0.68) | 4 (0.79) | 1 (0.39) | 0.864 |
Data were presented as median (IQR) or count (percentage).
AZA, azathioprine; C3, complement 3; C4, complement 4; CSA, ciclosporin; CYC, cyclophosphamide; dsDNA, double-stranded DNA; HCQ, hydroxychloroquine; HD, high dose; IV-CYC, intravenous cyclophosphamide; LEF, leflunomide; MMF, mycophenolate mofetil; MTX, methotrexate; NPSLE, neuropsychiatric SLE; RTX, rituximab; SILD, short interval, lower dose; SLEDAI, Systemic Erythematosus Disease Activity Index; TAC, tacrolimus.